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ABSTRACT
The prevalence of opioid misuse by people living with HIV (PLWH) during the current US opioid
epidemic has not been fully described. Among a cohort of persons engaged in HIV care in North
Carolina, we examined the prevalence of and risk factors for opioid misuse, defined as self-
reported “street” opioid use (e.g., heroin) or nonmedical prescription opioid use on a patient
reported outcomes survey. Recent (past three-month) opioid misuse among 1,440 PLWH in care
2012–2017 was 2% (95% CI 2-3%) and lifetime misuse 15% (13-16%). Persons reporting lifetime
or recent misuse more commonly had hepatitis C and reported injecting drugs. In multivariable
logistic regression models, male-to-male sexual contact was inversely associated with recent or
lifetime misuse. White/non-Hispanic race/ethnicity was associated with lifetime misuse and CD4
count and viral load were not associated with opioid misuse. Among 32 persons reporting
recent misuse, 81% had a contemporaneous viral load <50 copies/mL. In this cohort of PLWH
engaged in care, recent opioid misuse prevalence was similar to general population estimates.
Assessments of opioid misuse among PLWH not in care are urgently needed to fully characterize
the impact of opioids on all PLWH.
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The opioid epidemic has substantially impacted public
health in the United States (US). In addition to mounting
drug overdose deaths, opioids have also been linked to
outbreaks of HIV from injection drug use (IDU),
increases in hepatitis C and hospitalizations for severe
bacterial infections, such as infective endocarditis (Cen-
ters for Disease Control and Prevention, 2017; Cranston
et al., 2019; Peters et al., 2016; Ronan & Herzig, 2016).
According to national data, IDU-associated HIV diag-
noses are no longer declining in the US, and are increas-
ing among persons who are White, young, and reside in
the Midwest. (Lyss, Zhang, & Oster, 2018).
North Carolina (NC) has been significantly impacted
by the opioid crisis. Annual unintentional opioid over-
dose deaths have skyrocketed from 109 in
1999 to 1,384 in 2016 (Kansagra & Cohen, 2018). Mar-
kers of widespread IDU are apparent in NC, including
sharp rises in hepatitis C diagnoses and a twelve-fold
increase in IDU-related infective endocarditis (Kansagra
& Cohen, 2018; Schranz, Fleischauer, Chu, Wu, & Rosen,
2019). However, new HIV diagnoses have remained
stable from 2013–2017 (15.2-16.3 per 100,000), and the
proportion with IDU or combined IDU and male-to-
male sexual contact (MSM) as a risk factor have also
been essentially unchanged (North Carolina HIV/STD/
Hepatitis Surveillance Unit, 2018).
The impact of the opioid epidemic on persons already
living with HIV (PLWH) has not been well defined.
Although substance use disorders were found to be
highly prevalent among PLWH, present in 48% of per-
sons in a large multicenter cohort of persons in care,
opioid use disorder was the least common, affecting
only 4% (Hartzler et al., 2017). Other studies have gener-
ated conflicting estimates of the prevalence of past-year
opioid misuse among PLWH ranging from 3 to 12%
(Lemons et al., 2019; Turner et al., 2016). Yet, PLWH
may be at especially high risk of opioid misuse, as they
are frequently prescribed opioids for chronic pain and
receive higher doses than other populations. (Brunet,
Napravnik, Heine, Leone, & Eron, 2017; Edelman
et al., 2013).
Opioid misuse among PLWH poses a risk to both
patient and public health. Recent data has linked opioid
misuse to lower rates of viral suppression (Lemons et al.,
2019). Substance misuse is associated with adverse out-
comes among PLWH, such as non-receipt of antiretro-
viral therapy, poor retention in care and mortality
(DeLorenze, Weisner, Tsai, Satre, & Quesenberry,
2011; Meyer, Althoff, & Altice, 2013; Rebeiro et al.,
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2013). Improving HIV outcomes, such as viral suppres-
sion, among persons who misuse opioids can also help
stem ongoing transmission of HIV. PLWH who misuse
opioids and are not virally suppressed may pose a greater
risk at introducing HIV into networks of HIV-unin-
fected persons who use drugs. Substance misuse has
been linked to higher-risk sexual practices, such as con-
domless sex, in addition to IDU (Clayton, Lowry,
August, & Jones, 2016; Friedman et al., 2017). Under-
standing opioid misuse among PLWH in the setting of
the current opioid epidemic is foundational to identify-
ing opportunities to improve care and enhance pathways
for delivering medications for opioid use disorder.
In this study, we estimated the prevalence of recent
and lifetime opioid misuse in a large cohort of PLWH
in NC. We examined demographic and clinical factors
associated with opioid misuse, and the prevalence of
viral suppression among persons misusing opioids.
Methods
The University of North Carolina (UNC) Center for
AIDS Research HIV Clinical Cohort (UCHCC) collects
longitudinal clinical and demographic data on patients
≥18 years of age seen for HIV care at UNC (Napravnik
et al., 2006). For this study, we included all patients in
care from April 2012 to December 2017. Since April
2012, patients also complete computer-based patient
reported outcomes (PRO) surveys at four to six month
intervals during clinical visits (Fredericksen et al.,
2012). The PROs include the modified Alcohol, Smoking
and Substance Involvement Screening Test (ASSIST), a
brief instrument developed by the World Health Organ-
ization to screen for substance use in primary care.
ASSIST questions pertaining to illicit or prescription
opioid misuse ask about lifetime and past three-month
misuse (Supplemental Table 1).
Opioid misuse was defined as a response to either
“street” opioid use, such as heroin, or nonmedical use
of prescription opioids. Participants were categorized
as recent (any use in the past three months), ever (life-
time but not past three months) and never opioid mis-
use. Opioid misuse was the condition of interest, not
opioid use disorder, which is the psychiatric diagnosis
for a problematic pattern of opioid use. We chose opioid
misuse in order to broadly capture any participants at-
risk for drug-related HIV transmission, which may
include sexual transmission among drug using partners,
or transmission via IDU. Lifetime IDU was based on
PRO questions. MSM as transmission risk factor was
determined at the time of entry to care at UNC. Hepatitis
C status was based on abstracted diagnoses indicating
infection at any point during the study period or prior.
Viral suppression at PRO date was defined by the nearest
HIV RNA six months prior or three months after being
<50 copies/mL. CD4 count was determined by the near-
est CD4 twelve months prior or six months after the
PRO date.
We included data from the latest PRO reporting
recent opioid misuse. For those who reported lifetime
misuse but not recent misuse, we included the latest
PRO reporting lifetime misuse. For patients never
reporting any opioid misuse, the most recent PRO was
included. To estimate age and length of time in care
for all patients we used data most proximal to September
16, 2016 (the median date of PRO completion). This was
done to avoid making never misuse patients appear to
have older age and more years in care, since they were
evaluated based upon their most recent PRO available.
Unadjusted and multivariable logistic regression
models were created to evaluate the association between
demographic and clinical factors with (1) recent opioid
misuse, and (2) either recent or lifetime opioid misuse.
Multivariable models adjusted for age, gender, race/eth-
nicity, MSM, years in care, CD4 cell count and viral sup-
pression. Analyses were performed with SAS v9.4 (SAS
Institute, Cary, NC). The study was approved by the
UNC institutional review board.
Results
Of 2,170 participants in care during the study period,
1,545 completed at least one PRO. A total of 3,420
PROs were completed; however, we excluded 433
PROs due to nonresponse to questions pertaining to life-
time opioid misuse. Most (>69%) of the PROs with miss-
ing opioid misuse responses also had missing
information on other survey questions indicating the
PRO survey was not completed.
1,440 unique participants completed at least one eli-
gible PRO during the study period and were included
in the analysis. Of those, 35 or 2% (95% confidence inter-
val 2-3%) reported opioid misuse in the past three
months, 210 or 15% (13-16%) reported ever misusing
opioids in their life (but not in the past three months),
and 1,195 or 83% (81-85%) never misused opioids
(Table 1). Patients reporting lifetime misuse were older
than those reporting recent or never misuse (median
age 53, 51, 48 years, respectively). Black/non-Hispanic
was the most common race/ethnicity in all groups, com-
prising 56% overall. Median years in care differed
between recent misuse (5), lifetime misuse (11) and
never misuse (8). Self-reported lifetime IDU was more
common in recent (33%) or ever misuse (30%) vs.
never misuse (5%). Of persons reporting recent or life-
time opioid misuse, 81% and 90%, respectively, were
virally suppressed. The median CD4 cell count and pro-
portion of persons who were virally suppressed did not
differ across strata of opioid misuse.
In univariate models, patients reporting injection
drug use were more likely to report recent opioid misuse
(OR 3.87, 95% CI 1.82-8.24, Table 2). In multivariable
models, recent opioid misuse was inversely associated
with MSM (OR 0.33, 95% CI 0.12-0.86), but not associ-
ated with any other characteristic. When examining
recent or lifetime opioid misuse in univariate models,
older patients had an OR of 1.22 per ten-year increase
in age (95% CI 1.08-1.37) and White/non-Hispanic
race/ethnicity had an OR of 1.39 compared to Black/
non-Hispanic individuals (95% CI 1.04-1.86). Injection
drug use (8.62, 5.42-13.72), hepatitis C infection (3.83,
2.77-5.29) and years in care (1.02, 1.00-1.04) were also
associated with reporting either recent or lifetime opioid
misuse. In multivariable models, MSM was inversely
associated with recent or lifetime misuse (0.54, 0.36-
0.81). White/non-Hispanic race/ethnicity (1.72, 1.23-
2.40) was still associated with reporting either recent or
lifetime misuse in multivariable models.
In a sensitivity analysis using gender and MSM risk as
a combined variable in adjusted models, compared to
MSM, heterosexual men were more likely to report
recent misuse (3.07, 1.17-8.04) and recent or lifetime
misuse (1.85, 1.22-2.79), but there was no association
with women. To estimate the potential impact of adjust-
ing for hepatitis C infection and lifetime IDU, we con-
ducted two additional sensitivity analyses. In one
analysis including hepatitis C infection as a covariate,
adjusted estimates were similar to the main findings
for both recent misuse and recent or lifetime misuse,
but less precise, with an OR of recent or lifetime misuse
for MSM of 0.66 (0.43-1.01). Hepatitis C was associated
with recent or ever misuse use (3.53, 2.41-5.16) but not
recent misuse (1.45, 0.51-4.11). In a subgroup analysis
of patients with lifetime IDU and other covariates avail-
able (N = 721), in adjusted models also including both
hepatitis C infection and lifetime IDU, all estimates
were similar to the main findings but less precise, with
an OR comparing White/non-Hispanic to Black/non-
Hispanic patients of 1.45 (0.97-2.15). In that model
IDU was strongly associated with recent (4.21, 1.49-
11.93) and recent or lifetime misuse (6.71, 3.90-11.53)
but hepatitis C was no longer associated with either time-
frame of opioid misuse.
Discussion
In this cohort of PLWH who are engaged in HIV care,
prevalence of self-reported recent opioid misuse was
Table 1. Demographic and clinical characteristics of persons living with HIV, stratified by self-reported opioid misuse.a
Total
Recent
Ever Never(past 3 months)
n (%) n (%) n (%) n (%)
Total 1440 35 (2) 210 (15) 1,195 (83)
Age, median (IQR) 49 (38-56) 51 (34-55) 53 (43-60) 48 (38-55)
Male Gender 1,038 (72) 26 (74) 155 (74) 857 (72)
Race/Ethnicity
Black/non-Hispanic 802 (56) 21 (60) 104 (50) 677 (57)
White/non-Hispanic 490 (34) 12 (34) 88 (42) 390 (33)
Hispanic, Other, Unknown 148 (10) 2 (6) 18 (9) 128 (11)
MSMb
No 611 (42) 17 (49) 96 (46) 498 (42)
Yes 728 (51) 13 (37) 98 (47) 617 (52)
Lifetime Injection Drug Use c 102 (12) 11 (33) 62 (30) 29 (5)
Hepatitis Cd 208 (14) 9 (26) 69 (33) 130 (11)
Years in care, median (IQR)e 9 (4-16) 5 (2-15) 11 (5-17) 8 (4-15)
CD4 cell count, median (IQR) f 626 (436-853) 646 (366-950) 640 (410-858) 626 (440-850)
Viral Suppressiong
Suppressed 1,193 (87) 26 (81) 182 (90) 985 (87)
Not Suppressed, on ART 147 (11) 6 (19) 16 (8) 125 (11)
Not Suppressed, not on ART 31 (2) 0 5 (2) 26 (2)
Table 1 Legend: Results include clinical data and patient reported outcomes drawn from the University of North Carolina Center for AIDS Research Clinical Cohort
from April 2012 to December 2017.
aPrescription and illicit opioid misuse were assessed via self-report on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) measure.
bMSM, men who have sex with men, as transmission risk factor is based on abstraction from chart review. MSM was unknown for 101 participants (5, 16 and 80 for
recent, lifetime and never misuse, respectively).
cInjection drug use as self-reported on the ASSIST measure. Responses were missing for 612 participants (2, 6 and 604 for recent, lifetime and never misuse,
respectively).
dHepatitis C defined as ever being diagnosed with Hepatitis C by the end of the study period, as per information abstracted from the medical record.
eSince years in care was centered on September 16, 2016, 14 participants were coded as −1 year in care (0, 2 and 12 for recent, lifetime and never misuse,
respectively).
fCD4 count measured as cells/mm3. CD4 count results were missing for 45 participants (0, 6 and 39 for recent, lifetime and never misuse, respectively).
gViral suppression as determined by HIV RNA <50 copies/mL. ART, antiretroviral therapy, known use at the time of PRO response. Combined HIV RNA and ART
status was missing for 69 participants (3, 7 and 59 for recent, lifetime and never misuse, respectively).
2% between 2012 and 2017. White/non-Hispanic race/
ethnicity was associated with recent or lifetime opioid
misuse, and MSM contact was inversely associated
with recent or lifetime misuse. In sensitivity analyses,
compared to MSM, heterosexual men were more likely
to report recent or lifetime misuse. Among 32 persons
reporting recent opioid misuse with available viral
loads, 81% were recently virally suppressed. Viral sup-
pression and CD4 count were not associated with opioid
misuse.
Opioid misuse among PLWH in this cohort was gen-
erally consistent with estimates in the overall population
in North Carolina. In the 2015–2016 National Surveys
on Drug Use and Health (NSDUH), 4.7% and 0.4% of
persons over 18 years of age reported past-year prescrip-
tion pain reliever and heroin use, respectively (Substance
Abuse and Mental Health Services Administration,
2018).
Among PLWH, existing estimates of opioid misuse
vary widely. We found a slightly lower prevalence of mis-
use than in a large study of over 28,000 PLWH in the US
through the Medical Monitoring Project, which observed
a prevalence of opioid misuse of 3.3% over a past twelve-
month period (Lemons et al., 2019). That study found
that a lower proportion of persons misusing opioids
were virally suppressed (59%), compared with those
not misusing opioids (69%). An evaluation of PLWH
at two clinics in Ohio found that 11-12% reported non-
medical use of prescription opioids over the prior year, a
proportion that is over twice the estimate of 4.6% in the
general Ohio population (Substance Abuse and Mental
Health Services Administration, 2018; Turner et al.,
2016). Another study in two HIV clinics in Atlanta
and Boston found that, among PLWH prescribed
chronic opioids, 43% scored highly on a measure asses-
sing risk of past 30-day prescription opioid misuse,
and 5% reported illicit opioid use in the past year (Cola-
santi et al., 2018). Since previous studies have typically
captured the prevalence of past-year misuse, our findings
add additional information about the prevalence of even
more recent opioid misuse. These variations in the fre-
quency of opioid misuse within different populations
of PLWH may relate to regional differences in socioeco-
nomic contexts, drug use practices and physician opioid
prescribing, although further information is needed.
Half of our study population included persons with a
history of MSM, and we found that MSM was strongly
inversely associated with misusing opioids recently.
However, MSM, substance misuse and HIV do intersect
in NC, where roughly half of all new IDU-associated
HIV diagnoses from 2013–2017 included MSM as a
co-risk factor for transmission (North Carolina HIV/
STD/Hepatitis Surveillance Unit, 2018). HIV diagnoses
among persons with both MSM and IDU as risk factors
may represent use of drugs other than opioids, such as
methamphetamine, which is the most commonly
injected drug among MSM who are not HIV-infected
(Finlayson et al., 2011).
Table 2. Univariate and multivariable models of the association between demographic and clinic factors and recent or lifetime opioid 
misuse.
Unadjusted Odds Ratio (95% CI) Adjusted Odds Ratio (95% CI)
Recent Recent or Ever Recent Recent or Ever
Age, per 10-year increase 0.84 (0.64-1.10) 1.22 (1.08-1.37) 0.80 (0.57-1.13) 1.06 (0.92-1.22)
Male Gender 1.12 (0.52-2.42) 1.12 (0.82-1.52) 1.73 (0.64-4.62) 1.54 (0.99-2.38)
Race/Ethnicity
Black/non-Hispanic 1 1 1 1
White/non-Hispanic 0.93 (0.46-1.92) 1.39 (1.04-1.86) 1.28 (0.56-2.93) 1.72 (1.23-2.40)
Hispanic, Other, Unknown 0.51 (0.12-2.20) 0.85 (0.51-1.41) 0.58 (0.13-2.59) 0.97 (0.55-1.70)
MSMa
No 1 1 1 1
Yes 0.64 (0.31-1.32) 0.79 (0.60-1.06) 0.33 (0.12-0.86) 0.54 (0.36-0.81)
Lifetime Injection Drug Useb 3.87 (1.82-8.24) 8.62 (5.42-13.72) - -
Hepatitis Cc 2.10 (0.97-4.54) 3.83 (2.77-5.29) - -
Years in care 0.96 (0.91-1.01) 1.02 (1.00-1.04) 0.97 (0.91-1.03) 1.02 (1.00-1.04)
CD4 count, per 100-cell/µL increased 1.01 (0.91-1.12) 1.00 (0.96-1.04) 0.98 (0.86-1.11) 1.00 (0.95-1.05)
Viral Suppressione
Not Suppressed 1 1 1 1
Suppressed 0.72 (0.29-1.76) 1.24 (0.81-1.89) 0.85 (0.32-2.29) 1.07 (0.68-1.69)
Table 2 Legend: Results include clinical data and patient reported outcomes drawn from the University of North Carolina Center for AIDS Research Clinical Cohort
from April 2012 to December 2017.
aMSM, men who have sex with men, as transmission risk factor is based on abstraction from chart review. MSM was unknown for 101 participants (5, 16 and 80 for
recent, lifetime and never misuse, respectively).
bInjection drug use as self-reported on the ASSIST measure. Responses were missing for 612 participants (33, 204 and 591 for recent, lifetime and never misuse,
respectively).
cHepatitis C defined as ever being diagnosed with Hepatitis C by the end of the study period, as per information abstracted from the medical record.
dCD4 count modeled linearly. CD4 count results were missing for 45 participants (0, 6 and 39 for recent, lifetime and never misuse, respectively).
eViral suppression as determined by HIV RNA <50 copies/mL. HIV RNA was missing for 48 participants (3, 5 and 40 for recent, lifetime and never misuse,
respectively).
The demographic profile of PLWH reporting opioid
misuse in our study differed from the general population
affected by opioid overdoses in NC. In 2017, overdose
deaths were primarily White (86%), men (67%) and
aged 25–45 (55%) (Kaiser Family Foundation, n.d.).
Accordingly, this matched the profile of those involved
in a recent outbreak of HIV in another state linked to
injected opioids (Peters et al., 2016), in which persons
involved were largely young and white. Our population,
which was primarily middle-aged and Black, should call
attention to other demographic groups impacted by
opioids. Further, our population represents persons
with existing HIV diagnoses and who are engaged in
care. The proportion of PLWH in our study with sup-
pressed HIV RNA did not meaningfully differ by strata
of opioid misuse and was particularly high (81-90%),
exceeding the proportion of PLWH who are virally sup-
pressed in North Carolina overall (62%) (North Carolina
HIV/STD/Hepatitis Surveillance Unit, 2018). In addition
to indicating good clinical outcomes, this finding
suggests that only a small proportion of PLWH engaged
in care who misuse opioids may be at-risk of contribut-
ing to HIV transmission.
The strengths of this study include surveys on sub-
stance use among almost 1,500 patients combined with
clinical data, and being located in a US region severely
affected by both the HIV and opioid epidemics.We relied
on self-reported drug use behaviors. Although persons
might be reluctant to disclose these behaviors in a survey,
prior work using this questionnaire in a similar setting
suggests that PROs likely provide more reliable data on
substance use than electronic health records (Kozak
et al., 2012). Due to the nature of the data collected by
the modified ASSIST survey, our analysis focused on 3-
month and lifetime use, which makes direct comparisons
to the general population in the NSDUH challenging, and
does not explicitly ask about current use. Lastly, this study
included PLWH attending routine HIV care visits, and
our findings may not be generalizable to PLWH who
are not engaged in care. Out-of-care PLWH may have a
higher prevalence of ongoing opioid misuse and be less
likely to be virally suppressed, which would have impor-
tant implications for HIV transmission.
In summary, in this cohort of PLWH engaged in clini-
cal care in the Southeastern US, prevalence of recent
opioid misuse was 2.4%. Persons reporting recent or life-
time opioid misuse were largely virally suppressed and
had similar CD4 counts than those who never misused
opioids. Further studies evaluating opioid misuse, IDU
and viral suppression specifically among patients not
engaged in care are needed to elucidate the impact of
the opioid epidemic on PLWH across the spectrum of
engagement in care.
Disclosure statement
JJE is ad hoc consultant to ViiV healthcare, Gilead Sciences,
Merck and Janssen; and investigator on research contracts to
the University of North Carolina from ViiV Healthcare, Gilead
Sciences and Janssen. All other authors declare no conflicts.
Funding
This work was supported by the National Institutes of Health,
including the following grants: UNC Center for AIDS
Research grant P30AI50410 and the Center for AIDS Research
Network of Integrated Clinical Systems grant R24AI067039.
AJS is supported by the National Institute of Allergy and Infec-
tious Diseases (T32AI070114). TD is supported by the





Joseph J. Eron http://orcid.org/0000-0002-4938-0644
References
Brunet, L., Napravnik, S., Heine, A. D., Leone, P. A., & Eron, J.
J. (2017). Brief report: Longitudinal opioid use among HIV-
infected patients, 2000 to 2014. Journal of Acquired Immune
Deficiency Syndromes (1999), 75(1), 77–80. doi:10.1097/
QAI.0000000000001321.
Centers for Disease Control and Prevention. (2017). Viral
Hepatitis Surveillance: United States, 2015. Retrieved from
https://www.cdc.gov/hepatitis/statistics/2015surveillance/
pdfs/2015HepSurveillanceRpt.pdf
Clayton, H. B., Lowry, R., August, E., & Jones, S. E. (2016).
Nonmedical use of prescription drugs and sexual risk beha-
viors. Pediatrics, 137(1), e20152480. doi:10.1542/peds.2015-
2480.
Colasanti, J., Lira, M. C., Cheng, D. M., Liebschutz, J. M., Tsui,
J. I., Forman, L. S.,… del Rio, C. (2018). Chronic opioid
therapy in people living with Human Immunodeficiency
Virus: Patients’ perspectives on risks, monitoring, and
guidelines. Clinical Infectious Diseases, [Epub Ahead of
Print], doi:10.1093/cid/ciy452
Cranston, K., Alpren, C., John, B., Dawson, E., Roosevelt, K.,
Burrage, A.,…DeMaria, A. (2019). Notes from the field:
HIV diagnoses among persons who inject drugs -
Northeastern Massachusetts, 2015-2018. MMWR.
Morbidity and Mortality Weekly Report, 68(10), 253–254.
doi:10.15585/mmwr.mm6810a6.
DeLorenze, G. N., Weisner, C., Tsai, A.-L., Satre, D. D., &
Quesenberry, C. P. (2011). Excess mortality among HIV-
infected patients diagnosed with substance use dependence
or abuse receiving care in a fully integrated medical care
Program. Alcoholism, Clinical and Experimental Research,
35(2), 203–210. doi:10.1111/j.1530-0277.2010.01335.x.
Edelman, E. J., Gordon, K., Becker, W. C., Goulet, J. L.,
Skanderson, M., Gaither, J. R.,… Fiellin, D. A. (2013).
Receipt of opioid analgesics by HIV-infected and uninfected
patients. Journal of General Internal Medicine, 28(1), 82–90.
doi:10.1007/s11606-012-2189-z.
Finlayson, T. J., Le, B., Smith, A., Bowles, K., Cribbin, M.,
Miles, I.,… Centers for Disease Control and Prevention
(CDC). (2011). HIV risk, prevention, and testing behaviors
among men who have sex with men–national HIV behav-
ioral surveillance system, 21 U.S. Cities, United States,
2008. Morbidity and Mortality Weekly Report. Surveillance
Summaries (Washington, D.C.: 2002), 60(14), 1–34.
Fredericksen, R., Crane, P. K., Tufano, J., Ralston, J., Schmidt,
S., Brown, T.,… Crane, H. M. (2012). Integrating a web-
based, patient-administered assessment into primary care
for HIV-infected adults. Journal of AIDS and HIV
Research (Online), 4(2), 47–55.
Friedman, S. R., Mateu-Gelabert, P., Ruggles, K. V., Goodbody,
E., Syckes, C., Jessell, L.,…Guarino, H. (2017). Sexual risk
and transmission behaviors, partnerships and settings
among young adult nonmedical opioid users in New York
City. AIDS and Behavior, 21(4), 994–1003. doi:10.1007/
s10461-016-1672-7.
Hartzler, B., Dombrowski, J. C., Crane, H. M., Geng, E. H.,
Mathews, W. C., Mayer, K. H.,…Donovan, D. M. (2017).
Prevalence and predictors of substance use disorders
among HIV care enrollees in the United States. AIDS and
Behavior, 21(4), 1138–1148. doi:10.1007/s10461-016-1584-6.
Kaiser Family Foundation. (n.d.). Opioid Overdose Deaths.
Retrieved September 18, 2019, from https://www.kff.org/
state-category/health-status/opioids/
Kansagra, S. M., & Cohen, M. K. (2018). The opioid epidemic
in NC progress, challenges, and opportunities. North
Carolina Medical Journal, 79(3), 157–162. doi:10.18043/
ncm.79.3.157.
Kozak, M. S., Mugavero, M. J., Ye, J., Aban, I., Lawrence, S. T.,
Nevin, C. R.,…Willig, J. H. (2012). Patient reported out-
comes in routine care: Advancing data capture for HIV
cohort research. Clinical Infectious Diseases: An Official
Publication of the Infectious Diseases Society of America,
54(1), 141–147. doi:10.1093/cid/cir727.
Lemons, A., DeGroote, N., Peréz, A., Craw, J., Nyaku, M., Broz,
D.,… Beer, L. (2019). Opioid misuse among HIV-positive
adults in medical care: Results from the medical monitoring
project, 2009–2014. JAIDS Journal of Acquired Immune
Deficiency Syndromes, 80(2), 127. doi:10.1097/QAI.
0000000000001889.
Lyss, S., Zhang, T., & Oster, A. (2018). HIV Diagnoses among
people who inject drugs - United States, 2010-2016.
Presented at the Conference on Retroviruses and




Meyer, J. P., Althoff, A. L., & Altice, F. L. (2013).
Optimizing care for HIV-infected people who use drugs: evi-
dence-based approaches to overcoming healthcare dispar-
ities. Clinical Infectious Diseases, 57(9), 1309–1317. doi:10.
1093/cid/cit427.
Napravnik, S., Eron, J. J., McKaig, R. G., Heine, A. D., Menezes,
P., & Quinlivan, E. (2006). Factors associated with fewer vis-
its for HIV primary care at a tertiary care center in the
Southeastern U.S. AIDS Care, 18(sup1), 45–50. doi:10.
1080/09540120600838928.
North Carolina HIV/STD/Hepatitis Surveillance Unit. (2018).
2017 North Carolina HIV/STD/Hepatitis Surveillance
Report. Retrieved from https://epi.publichealth.nc.gov/cd/
stds/figures/std17rpt_rev12142018.pdf
Peters, P. J., Pontones, P., Hoover, K. W., Patel, M. R., Galang,
R. R., Shields, J.,…Duwve, J. M. (2016). HIV infection
linked to injection use of Oxymorphone in Indiana, 2014–
2015. New England Journal of Medicine, 375(3), 229–239.
doi:10.1056/NEJMoa1515195.
Rebeiro, P., Althoff, K. N., Buchacz, K., Gill, M. J., Horberg, M.,
Krentz, H.,…Gange, S. J. (2013). Retention among North
American HIV–infected persons in clinical care, 2000–
2008. Journal of Acquired Immune Deficiency Syndromes
(1999), 62(3), 356–362. doi:10.1097/QAI.0b013e3182
7f578a.
Ronan, M. V., & Herzig, S. J. (2016). Hospitalizations related
To opioid abuse/dependence and associated serious infec-
tions increased sharply, 2002–12. Health Affairs, 35(5),
832–837. doi:10.1377/hlthaff.2015.1424.
Schranz, A. J., Fleischauer, A., Chu, V. H., Wu, L.-T., & Rosen,
D. L. (2019). Trends in drug use-associated infective endo-
carditis and heart valve surgery, 2007 to 2017: A study of
Statewide Discharge data. Annals of Internal Medicine,
170(1), 31. doi:10.7326/M18-2124. PMID: 30508432.
Substance Abuse and Mental Health Services Administration.
(2018). 2015-2016 NSDUH State-Specific Tables. Retrieved
from https://www.samhsa.gov/data/report/2015-2016-
nsduh-state-specific-tables
Turner, A. N., Maierhofer, C., Funderburg, N. T., Snyder, B.,
Small, K., Clark, J.,… Kwiek, J. J. (2016). High levels of
self-reported prescription opioid use by HIV-positive indi-
viduals. AIDS Care, 28(12), 1559–1565. doi:10.1080/
09540121.2016.1198746.
